Use of mGluR5 antagonists for the treatment of gerd
View Patent ↗The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation.
1. A method for the inhibition of transient lower esophageal sphincter relaxations (TLESRs) in a patient suffering from gastroesophageal reflux disease (GERD), the method comprising administering a therapeutically effective amount of a compound which is a metabotropic glutamate receptor 5 antagonist, a pharmaceutically acceptable salt of the compound, an optical isomer of the compound or a pharmaceutically acceptable salt of the optical isomer, to the patient.
2. A method for the treatment of gastro-esophageal reflux disease (GERD), the method comprising administering a therapeutically effective amount of a compound which is a metabotropic glutamate receptor 5 antagonist, a pharmaceutically acceptable salt of the compound, an optical isomer of the compound or a pharmaceutically acceptable salt of the optical isomer, to a patient suffering from gastroesophageal reflux disease.
3. A method for the inhibition of reflux of gastric juice in a patient suffering from gastroesophageal reflux disease (GERD), the method comprising administering a therapeutically effective amount of a compound which is a metabotropic glutamate receptor 5 antagonist, a pharmaceutically acceptable salt of the compound, an optical isomer of the compound or a pharmaceutically acceptable salt of the optical isomer, to the patient.
4. A method for the treatment of regurgitation of gastric juice in a patient suffering from gastroesophageal reflux disease (GERD), the method comprising administering a therapeutically effective amount of a compound which is a metabotropic glutamate receptor 5 antagonist, a pharmaceutically acceptable salt of the compound, an optical isomer of the compound or a pharmaceutically acceptable salt of the optical isomer, to the patient.
5. The method according to any one of claims 1 - 4 , wherein the metabotropic glutamate receptor 5 antagonist is 2-methyl-6-(phenylethynyl)-pyridine.
6. The method according to claim 5 , wherein the metabotropic glutamate receptor 5 antagonist is the hydrochloride salt of 2-methyl-6-(phenylethynyl)-pyridine.
7. The method according to any one of claims 1 - 4 , wherein the metabotropic glutamate receptor 5 antagonist is 3-[3-(5-fluoropyridin-2-yl)-1,2, oxadiazol-5-yl]-5-(methoxymethyl)benzonitrile.
8. The method according to any one of claims 1 - 4 , wherein the metabotropic glutamate receptor 5 antagonist is 3-fluoro-5-[3-(5-fluoropyridin-2-yl)-1,2,4-oxadiazol-5-yl]benzonitrile.
9. The method according to any one of claims 1 - 4 , wherein the daily dose of the metabotropic glutamate receptor 5 antagonist is from 0.1-100 mg per kg body weight of the subject to be treated.